Siren L.L.C. Has $76.67 Million Position in Xenon Pharmaceuticals Inc. $XENE

Siren L.L.C. increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 62.2% during the 1st quarter, Holdings Channel reports. The fund owned 1,318,564 shares of the biopharmaceutical company’s stock after acquiring an additional 505,803 shares during the period. Xenon Pharmaceuticals comprises approximately 2.1% of Siren L.L.C.’s investment portfolio, making the stock its 11th largest position. Siren L.L.C.’s holdings in Xenon Pharmaceuticals were worth $76,674,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also bought and sold shares of the company. Danske Bank A S bought a new stake in Xenon Pharmaceuticals in the third quarter valued at $32,000. Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 717 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth about $33,000. Osaic Holdings Inc. grew its stake in shares of Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,034 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $65.42 on Friday. Xenon Pharmaceuticals Inc. has a one year low of $30.00 and a one year high of $72.66. The company has a market cap of $6.32 billion, a PE ratio of -13.92 and a beta of 0.61. The firm has a 50-day moving average of $58.08 and a 200-day moving average of $52.53.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the prior year, the firm posted ($0.83) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on XENE shares. JPMorgan Chase & Co. upped their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Royal Bank Of Canada raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Needham & Company LLC decreased their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $77.20.

Insider Activity at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.